Lilly to acquire scorpion therapeutics' mutant-selective pi3kΑ inhibitor program

The acquisition will expand lilly's oncology pipeline with stx-478, the differentiated and potentially best-in-class, mutant-selective pi3k Α inhibitor currently in a phase 1/2 clinical trial stx-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on lilly's advancements against this disease indianapolis and boston, mass. , jan. 13, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) and scorpion therapeutics, inc. ("scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for lilly to acquire scorpion's pi3kΑ inhibitor program stx-478.
STX Ratings Summary
STX Quant Ranking